AR083241A1 - Metodos y kits para el diagnostico de cancer de prostata - Google Patents

Metodos y kits para el diagnostico de cancer de prostata

Info

Publication number
AR083241A1
AR083241A1 ARP110102567A ARP110102567A AR083241A1 AR 083241 A1 AR083241 A1 AR 083241A1 AR P110102567 A ARP110102567 A AR P110102567A AR P110102567 A ARP110102567 A AR P110102567A AR 083241 A1 AR083241 A1 AR 083241A1
Authority
AR
Argentina
Prior art keywords
prostate
methods
subject
prostate cancer
kits
Prior art date
Application number
ARP110102567A
Other languages
English (en)
Inventor
Andreas Doll
Resina Marina Rigau
Robles Juan Morote
Posada Miguel Abal
Puigjaner Jaume Reventos
Original Assignee
Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada filed Critical Fundacio Inst De Recerca Hospital Uni Vall D & Rsquo Hebron Fundacio Privada
Publication of AR083241A1 publication Critical patent/AR083241A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente se refiere a métodos y kits para el diagnostico de cáncer de próstata (CAP) en un sujeto, para evaluar o seguir la respuesta a una terapia en un sujeto que tiene cáncer de próstata (CAP) o para seguir la evolución del cáncer de próstata (CAP) basados en la detección de cambios en los niveles de expresión de al menos un gen seleccionado del grupo antígeno de cáncer de próstata 3 (PCA3), antígeno de membrana específico de próstata (PSMA) y receptor acoplado de proteína G específico de próstata (PSGR). La presente se refiere a si mismo a métodos para evaluar si un sujeto se tiene que someter a una biopsia de próstata, dicho sujeto tiene PSA en suero en el intervalo de 4 - 10 hg/ml.
ARP110102567A 2010-07-14 2011-07-15 Metodos y kits para el diagnostico de cancer de prostata AR083241A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382193A EP2407554A1 (en) 2010-07-14 2010-07-14 Methods and kits for the diagnosis of prostate cancer

Publications (1)

Publication Number Publication Date
AR083241A1 true AR083241A1 (es) 2013-02-13

Family

ID=42670648

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102567A AR083241A1 (es) 2010-07-14 2011-07-15 Metodos y kits para el diagnostico de cancer de prostata

Country Status (5)

Country Link
US (1) US20130171653A1 (es)
EP (2) EP2407554A1 (es)
AR (1) AR083241A1 (es)
TW (1) TW201217785A (es)
WO (1) WO2012007546A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153441A1 (en) 2014-03-31 2015-10-08 University Of Washington Methods and systems for selectively disrupting tissue with high intensity focused ultrasound
ES2914727T3 (es) * 2017-02-13 2022-06-15 Genomic Health Inc Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata
CN108441557A (zh) * 2018-01-31 2018-08-24 广州瑞博奥生物科技有限公司 Pca3和psa基因检测试剂盒及其应用
US20230416359A1 (en) * 2020-06-17 2023-12-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
WO1998024935A1 (en) 1996-12-06 1998-06-11 Urocor, Inc. Diagnosis of disease state using mrna profiles
ES2402947T3 (es) 1997-04-10 2013-05-10 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, genes PCA3 y métodos de uso
WO2001000235A1 (en) 1999-06-29 2001-01-04 Mcgill University Prion protein binding proteins and uses thereof
AU2002245727A1 (en) * 2001-04-05 2002-10-21 The Henry M. Jackson Foundation Enhanced diagnostic potential of prostate-specific antigen expressing cells
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
DE102006032394B4 (de) * 2006-03-17 2011-07-07 Technische Universität Dresden, 01069 Verfahren zur Diagnose und Differenzierung von Prostatakrebs
EP2155897A2 (en) 2007-03-30 2010-02-24 Source Precision Medicine, Inc. d/b/a Source MDX. Gene expression profiling for identification, monitoring, and treatment of prostate cancer
AU2008354371B2 (en) * 2008-04-10 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
CA2723143A1 (en) 2008-05-01 2009-11-05 Martin G. Sanda Methods and compositions for prostate cancer immunotherapy

Also Published As

Publication number Publication date
US20130171653A1 (en) 2013-07-04
EP2593561A1 (en) 2013-05-22
TW201217785A (en) 2012-05-01
EP2407554A1 (en) 2012-01-18
WO2012007546A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
CR20120371A (es) Antagonistas de pcsk9
EA201600085A1 (ru) Набор для обнаружения соевого события syht0h2
MX367366B (es) Composiciones y metodos para diagnosticar tumores de tiroides.
EA201400710A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
EA201792497A1 (ru) Антитела к gitr для диагностики злокачественной опухоли
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
AR080505A1 (es) Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
BR112012018132A2 (pt) "marcadores de células - tronco tumorais e uso dos mesmos".
BR112012029281A2 (pt) anticorpo trop-2 anti-humano tendo atividade anti-tumor in vivo
EP4242329A3 (en) Use of markers including filamin a in the diagnosis and treatment of prostate cancer
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
AR079340A1 (es) Anticuerpos anti-c4.4a y usos de los mismos
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
ES2530743T3 (es) Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa
EA201590650A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata
AR089028A1 (es) Composiciones y metodos para el analisis de cancer de prostata
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
BR112015031950A2 (pt) métodos para tratamento de câncer de ovário

Legal Events

Date Code Title Description
FB Suspension of granting procedure